Figure 3.

Tumor-Derived Prostanoids Prevent CD103⁺ DC Accumulation and Activation

(A and B) WT mice were inoculated with 10⁶ parental or Ptgs1/Ptgs2^−/− Braf^V600E cells and tumor-infiltrating DCs were analyzed 4 days later. (A) Left: representative fluorescence-activated cell sorting (FACS) plots for CD103 versus CD11b within a CD11c⁺ MHCII⁺ DC gate. Right: percentage and number (#) of CD103⁺ CD11c⁺ MHCII⁺ or CD11c⁺ MHCII⁺ cells. (B) Upper: representative FACS plots for CD11c versus IL-12p40 or CD86 versus CD40 within a CD103⁺ or CD11b⁺ CD11c⁺ MHCII⁺ gate. Lower: percentage of IL-12p40⁺ or CD86⁺ CD40⁺ within CD103⁺ or CD11b⁺ CD11c⁺ MHCII⁺ cells. Each symbol in (A) and (B) represents an independent tumor. Samples were compared using two-tailed Student’s t test. ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001.